Viva Biotech Holdings · HKEX:1873
Viva Biotech — FY2022 Earnings Presentation
27 slides from Viva Biotech's earnings presentation, Mar 31, 2023
Slide 1: Viva Biotech 2022 Annual Results
Viva Biotech 2022 Annual Results 31 March 2023 Shanghai, China
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain information set forth in this presentation contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our managemen
Slide 3: Contents
01 Business Highlights 02 Financial Performance CONTENTS 03 Future Strategies Q&A Session
Slide 4: Part 1: Business Highlights
CP iva PART 1: Business Highlights
Slide 5: World Leading One-stop Drug Research and Production Platform
World Leading One-stop Drug Research and Production Platform CRO Business CDMO Research and Production EFS Investment & Incubation Business Business Focus on FIC's Discover business, take Provide innovative drug partners with small Focus on discovering and investing in SBDD as the core to drive FBDD
Slide 6: Continued to Build Technology Barriers, Improved CRO-CDMO Service Capabilities
Continued to Build Technology Barriers, Improved CRO-CDMO Service Capabilities as a One-stop Platform SBDD FBDD Compound design Viva Fragment Library Viva Compound Library CADD Computational Chemistry & Research and development expenses were ASMS screening platform SEC-ASMS Biology approximately R
Slide 7: Overview
Overview Business Highlights Revenue: RMB 2380 million, +13.0% YOY Gross profit: RMB 816 million, +25.3% YOY Adjusted net profit: RMB -133.9 million, a decrease YOY Adjusted basic earnings per share: RMB -0.28 2380 The Group’s total no. of clients: 2076, widely located in North America, Eu
Slide 8: CRO: Revenue and Gross Profit with Steady Growth
Overview CRO：Revenue and Gross Profit with Steady Growth and Favorable Backlog 54.1 Revenue: RMB 895.1 million, +20.9% YOY Gross profit: RMB 397 million, +14% YOY 85.8 Revenue from Top 10 customers accounted for 24.6% Revenue from Overseas accounted for 85.4%, increase by 23.2% YOY Revenue
Slide 9: CRO: Numbers of Customers and R&D Staff with Continuous Growth
CRO：Numbers of Customers and R&D Staff with Continuous Growth and Favorable Backlog Order backlog: +8.8% RMB million No. of CRO R&D staff: +33.5% 2022 1050 2022 1617 2021 965 2021 1211 2020 607 2020 817 Served Top 10 global pharmaceutical companies No. of CRO customers: +19% 2022 1224 (by reported t
Slide 10: CRO: Expanding Scale with No. of Targets and Protein Structures Delivered
CRO: Expanding Scale with No. of Targets and Protein Structures Delivered Radiation source usage Hours No. of targets and protein structures delivered 2022 2064 Independent targets: +68 2021 1934 2020 1428 Cumulative Number 1878 Use 12 synchrotron radiation source centers around the world Co
Slide 11: CDMO R&D and Production Services Overview
Overview CDMO R&D and Production Services Langhua’s revenue: RMB 1485 million, +8.8% YOY Langhua’s adjusted gross profit: RMB 433 million, +33.6% YOY 305 CDMO: revenue RMB 885 million, +21.23% YOY; adjusted gross profit 373 margin 38.42%, +2.53pp YOY 295 API: revenue RMB 295 million, +13.03%
Slide 12: CDMO: Continuous Volume Growth in Heavy Pipelines
CDMO : Continuous Volume Growth in Heavy Pipelines, Steady Sales Growth Driven by Recovery in Production Capacity Revenue and gross profit from CDMO RMB Million Production capacity expansion plan (21-23E) Cubic metre 2024E 1260 2023E 860 2022 860 885 730 Langhua plans to build a new capacity of 40
Slide 13: Continue to Strengthen CMC Capacity Building with Increasing Revenue
Continue to Strengthen CMC Capacity Building with Increasing Revenue Revenue scale RMB CMC staff 2022 155 ～RMB 50 million 2021 120 ～RMB 10 million 2021 2022 2023E Internal and external two-pronged approach for CMC diversion Revenue of CMC: approx. RMB 50 million. Due to the continuous increase in
Slide 14: EFS Investment & Incubation Business Overview
Overview EFS Investment & Incubation Business RMB million Completed 15 investments in 2022, of which 4 were newly-added 1419 As of Dec 31, 2022, invested in a total of 91 portfolio companies 1241.2 In 2022, 2 of the portfolio companies achieved partial or complete exit 1100.7 1047 215 Pipeli
Slide 15: VBI Business
VBI Business As of Dec 31, 2022，VBI invested in a total of 91 projects, reviewed 455 projects, added 4 companies into portfolio, added 2 new investment funds, and followed on 9 additional investment projects In 2022, 2 of the portfolio companies made partial or complete exit New Project Follow-o
Slide 16: High-speed Pipeline Expansion & Smooth Progress in Financing
High-speed Pipeline Expansion & Smooth Progress in Financing 215 pipeline projects in portfolio companies • Ischaemic stroke *in terms of total no. of portfolio companies pipeline entered phase II 215 clinical trials 2021 2022 185 • ANJ900 entered phase III clinical trial; • ANJ908 entered phase II
Slide 17: Part 2: Financial Performance
PART 2: Financial Performance
Slide 18: Financial Performance of the Group
Financial Performance of the Group Rapid Growth in Revenue RMB million RMB million Adjusted Gross Profit Increased 13.0% Increased 23.5% 2380 831 2104 673 2021 2022 2021 2022 Adjusted Net Profit RMB million Adjusted EBITDA RMB million 521 321.1 Decreased 82.5% YoY Decreased 141.7% YoY -133.9 2021 20
Slide 19: CRO BU Financial Statistics
CRO BU Financial Statistics CRO revenue RMB million RMB million Adjusted Gross profit Increased 21% 895 Increased 14.0% 740 398 349 2021 2022 2021 2022 No. of CRO R&D personnel Annual revenue per CRO Personnel RMB’000 Increased 33.5% Decreased 6.8% 1617 1211 653.6 609.3 2021 2022 2021 2022 www.vivab
Slide 20: CDMO BU Financial Statistics
CDMO BU Financial Statistics Langhua’s revenue RMB million Langhua’s adjusted gross profit RMB million Increased 8.9% Increased 33.6% 1485 1364 433 324 2021 2022 2021 2022 www.vivabiotech.com 20
Slide 21: Revenue Classifications of Principal Activities
Revenue Classifications of Principal Activities For the 12 months ended DEC 31, 2022 CDMO and commercialisation Drug discovery services Total services Types of goods or services RMB’000 RMB’000 RMB’000 Revenue from non-investees Full-time-equivalent (FTE) 667,165 - 667,165 Fee-for-service (FFS) 126,
Slide 22: Items Measured at Fair Value with Changes Recognised in Profit or Loss
Items Measured at Fair Value with Changes in Fair Value Recognised in Profit or Loss The movements in the carrying value of unlisted investments at FVTPL for the reporting period are as follows： RMB’000 At January 1, 2021 924,532 Acquired 249,517 Recognized from SFE revenue 86,438 Recognised from de
Slide 23: Part 3: Future Strategies
CP iva PART 3: Future Strategies
Slide 24: Improve Capacity Building for Front-end Projects, Expand Whole Industry Chain Service
Improve Capacity Building for Front-end Projects, Continue to Expand the Whole Industry Chain Service Downstream To establish an open and cooperative platform and a win-win Early-stage ecosystem for global biopharmaceutical innovators pre-clinical service Raise technology barriers and Expand servi
Slide 25: Appendix: Adjusted Non-IFRS Net Profit
APPENDIX: Adjusted Non-IFRS Net Profit 2022 2022H1 2021 2021H1 2020 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Net Profit/ (Loss) -504,220 -85,220 300,560 95,802 -378,870 Add: fair value (gain) loss on embedded derivative -10,050 -10,050 -143,590 13,366 547,048 instrument of convertible bonds Add: inte
Slide 26: Q&A Session
CP iva Q&A Session
Slide 27: Thank You
THANK YOU！ Ir@vivabiotech.com Viva Biotech Holdings No.735, Ziping Road, Pudong New Area, Shanghai 201318, China —— Tel: +86 21 6089 3288 E-mail: info@vivabiotech.com www.vivabiotech.com